Why Corcept Therapeutics (CORT) is a Top Growth Stock for the Long-Term
Werte in diesem Artikel
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.The Style Scores are broken down into four categories:Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank. How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.That's where the Style Scores come in.To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. Stock to Watch: Corcept Therapeutics (CORT) Redwood City, CA-based Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone.CORT is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.Additionally, the company could be a top pick for growth investors. CORT has a Growth Style Score of B, forecasting year-over-year earnings growth of 53.7% for the current fiscal year.Two analysts revised their earnings estimate higher in the last 60 days for fiscal 2025, while the Zacks Consensus Estimate has increased $0.05 to $1.89 per share. CORT also boasts an average earnings surprise of 20.1%.With a solid Zacks Rank and top-tier Growth and VGM Style Scores, CORT should be on investors' short list.Should You Invest in Corcept Therapeutics Incorporated (CORT)?Before you invest in Corcept Therapeutics Incorporated (CORT), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: Corcept Therapeutics und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf Corcept Therapeutics
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Corcept Therapeutics
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Corcept Therapeutics Inc.
Analysen zu Corcept Therapeutics Inc.
Datum | Rating | Analyst | |
---|---|---|---|
04.02.2019 | Corcept Therapeutics Neutral | B. Riley FBR | |
10.08.2018 | Corcept Therapeutics Hold | Stifel, Nicolaus & Co., Inc. | |
31.05.2018 | Corcept Therapeutics Hold | Stifel, Nicolaus & Co., Inc. | |
09.03.2018 | Corcept Therapeutics Buy | B. Riley FBR, Inc. | |
31.08.2017 | Corcept Therapeutics Buy | Stifel, Nicolaus & Co., Inc. |
Datum | Rating | Analyst | |
---|---|---|---|
10.08.2018 | Corcept Therapeutics Hold | Stifel, Nicolaus & Co., Inc. | |
31.05.2018 | Corcept Therapeutics Hold | Stifel, Nicolaus & Co., Inc. | |
09.03.2018 | Corcept Therapeutics Buy | B. Riley FBR, Inc. | |
31.08.2017 | Corcept Therapeutics Buy | Stifel, Nicolaus & Co., Inc. | |
21.04.2015 | Corcept Therapeutics Outperform | FBR Capital |
Datum | Rating | Analyst | |
---|---|---|---|
04.02.2019 | Corcept Therapeutics Neutral | B. Riley FBR | |
28.08.2006 | Update Corcept Therapeutics Inc.: Market Perform | Punk, Ziegel & Co |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Corcept Therapeutics Inc. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen